AUTHOR=Zhang Xi-Ru , Li Zhi-Qiang , Sun Li-Xin , Liu Ping , Li Zhi-Hao , Li Peng-Fei , Zhao Hong-Wei , Chen Bi-Liang , Ji Mei , Wang Li , Kang Shan , Lang Jing-He , Mao Chen , Chen Chun-Lin 

TITLE=Cohort Profile: Chinese Cervical Cancer Clinical Study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.690275

DOI=10.3389/fonc.2021.690275

ISSN=2234-943X

ABSTRACT=Abstract
Cervical cancer is the fourth most common cancer worldwide, but incidence widely varies in different countries. China accounts for approximately 18% of the world’s cervical cancer burden, regardless of incidence or mortality. The Chinese Cervical Cancer Clinical Study is a hospital-based multicenter open cohort. The major aims include (i) exploring the associations of therapeutic strategies with complications as well as mid- and long-term clinical outcomes; (ii) widely assessing the factors which may have an influence on the prognosis of cervical cancer to guide the treatment options and estimating prognosis using a prediction model for precise post-treatment care and follow-up; (iii) developing a knowledge base of cervical clinical auxiliary diagnosis and prognosis prediction using artificial intelligence and machine learning approaches; and (iv) roughly mapping the burden of cervical cancer in different districts and monitoring the trend in incidence of cervical cancer to potentially inform prevention and control strategies. 
Patients eligible for inclusion were diagnosed with cervical cancer, whether during an outpatient visit or hospital admission, at 47 different types of medical institutions in 19 cities of 11 provinces across mainland China between 2003 and 2020. As of September 10, 2020, a total of 63 926 patients with cervical cancer were enrolled in the cohort. 
Since the project inception, standardized variables have been collected, including epidemiological characteristics, cervical cancer-related symptoms, physical examination results, laboratory testing results, imaging reports, tumor biomarkers, tumor staging, tumor characteristics, comorbidities, co-infections, treatment and short-term complications. 
Follow-up was performed at least once every 6 months within the first 5 years after receiving treatment and then annually thereafter. At present, we are developing a cervical cancer imaging database containing Dicom files with data of computed tomography/magnetic resonance imaging examination. Additionally, we are also collecting original pathological specimens of patients with cervical cancer.
Potential collaborators are welcomed to contact the corresponding authors and anyone can submit at least one specific study proposal describing the background, objectives and methods of the study.